NYSEARCA:XTNT - NYSE Arca - US98420P3082 - Common Stock - Currency: USD
0.682
-0.05 (-7.44%)
The current stock price of XTNT is 0.682 USD. In the past month the price increased by 42.11%. In the past year, price decreased by -5.28%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 28.9 | 43.32B | ||
COO | COOPER COS INC/THE | 21.38 | 16.12B | ||
ALGN | ALIGN TECHNOLOGY INC | 19.14 | 12.94B | ||
SOLV | SOLVENTUM CORP | 12.19 | 12.55B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 27.03 | 5.70B | ||
LNTH | LANTHEUS HOLDINGS INC | 11.44 | 5.24B | ||
BLCO | BAUSCH + LOMB CORP | 24.58 | 4.17B | ||
HAE | HAEMONETICS CORP/MASS | 14.88 | 3.42B | ||
XRAY | DENTSPLY SIRONA INC | 9.73 | 3.26B | ||
ICUI | ICU MEDICAL INC | 18.69 | 3.21B | ||
UFPT | UFP TECHNOLOGIES INC | 28.96 | 1.82B | ||
NEOG | NEOGEN CORP | 16.18 | 1.33B |
Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 217 full-time employees. The company went IPO on 2010-06-30. The firm is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. The company offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, Interbody products and Interlaminar Stabilization products.
XTANT MEDICAL HOLDINGS INC
664 Cruiser Lane
Belgrade Montana MONTANA 59714 US
CEO: Sean E. Browne
Employees: 225
Phone: 14063880480
The current stock price of XTNT is 0.682 USD. The price decreased by -7.44% in the last trading session.
The exchange symbol of XTANT MEDICAL HOLDINGS INC is XTNT and it is listed on the NYSE Arca exchange.
XTNT stock is listed on the NYSE Arca exchange.
8 analysts have analysed XTNT and the average price target is 1.79 USD. This implies a price increase of 161.73% is expected in the next year compared to the current price of 0.682. Check the XTANT MEDICAL HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
XTANT MEDICAL HOLDINGS INC (XTNT) has a market capitalization of 95.02M USD. This makes XTNT a Micro Cap stock.
XTANT MEDICAL HOLDINGS INC (XTNT) currently has 225 employees.
XTANT MEDICAL HOLDINGS INC (XTNT) has a support level at 0.68 and a resistance level at 0.74. Check the full technical report for a detailed analysis of XTNT support and resistance levels.
The Revenue of XTANT MEDICAL HOLDINGS INC (XTNT) is expected to grow by 9.24% in the next year. Check the estimates tab for more information on the XTNT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
XTNT does not pay a dividend.
XTANT MEDICAL HOLDINGS INC (XTNT) will report earnings on 2025-08-06, before the market open.
XTANT MEDICAL HOLDINGS INC (XTNT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.09).
The outstanding short interest for XTANT MEDICAL HOLDINGS INC (XTNT) is 0.05% of its float. Check the ownership tab for more information on the XTNT short interest.
ChartMill assigns a technical rating of 9 / 10 to XTNT. When comparing the yearly performance of all stocks, XTNT is one of the better performing stocks in the market, outperforming 84.22% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to XTNT. XTNT may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months XTNT reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS decreased by -800% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -12.51% | ||
ROE | -27.33% | ||
Debt/Equity | 0.51 |
ChartMill assigns a Buy % Consensus number of 85% to XTNT. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 70.25% and a revenue growth 9.24% for XTNT